Diabetes and heart risk. My goodness do we hear a lot about that. And for good reason: people with diabetes are 2-4 times more likely to develop atherosclerosis (hardening of the blood vessels) and five times more likely to have a stroke than people without diabetes, according to the ADA.  Yipes! And then there's the uproar of late about diabetes drugs that possibly increase the risk of heart attack (although the evidence on Avandia apparently wasn't conclusive enough to pull the drug off the market).  Some of us are worried that the current climate of fear may be creating some very negative consequences:

1) As the Washington Post points out: "The concern now is that worries over heart attack have led many people to leave their diabetes untreated, abandoning their medication without picking up other drugs or other means of controlling the disease." Lets not forget that untreated diabetes causes the biggest risk — and not only of heart attack, but many other nasty complications as well.

2) Many leaders in the D-patient community are concerned that tightening FDA regulations will end up serving to quash innovation and slow development of many potentially positive new treatments. (More about that HERE.)

But what IHeart really wanted to highlight today was a new heart risk test on the market from a New Jersey-based company called Synvista Therapeutics.  They've developed a sophisticated genetic test that may be useful for those who REALLY WANT OR NEED TO KNOW how high their cardiovascular risk factors stand.

The test determines whether you are producing a particular variant of a blood protein called haptoglobin (Hp for short) that may increase your risk of heart disease.  "Since this test determines which diabetic patients display the highest levels of oxidative stress (Hp 2-2 individuals) it can also be used to identify the subset of diabetics who will benefit most from potent anti-oxidizing agents," the company's website explains.  In other words, the test could suggest anti-oxidant therapy as an intervention in case you turn up to be in the highest risk class for cardiovascular disease.

You can read details about the haptoglobin test in the latest issue of the excellent patient newsletter diaTribe.  Note that the test costs $325, and is so new that it is not yet reimbursed by most insurance companies.  In fact, many doctors may not even know about it yet.

Nevertheless, diaTribe Editor Kelly Close actually took the new test for a "test drive" herself, following this simple procedure:

  1. Get a blood draw prescription from your healthcare provider.
  2. Have your blood drawn at your local lab.
  3. Have your lab send the sample sent to the ARUP lab in Salt Lake City with a request for a Haptoglobin (HP) Genotyping PCR — code number 0040116
  4. The results will be sent to your physician in 2-7 days.
  5. Work with your physician and healthcare team to develop an appropriate plan of action based on the results.

She points out that you might be able to secure insurance coverage "with the right letter from your doctor" — if you have special reason to be very worried about your cardiovascular risk.  That would of course include folks whose glycemic control has been pretty poor for a while.  Taking the test "may help you better manage your risk or may help your motivation to do so," she notes.

Or, another way to go about it would be to enter diaTribe's current promotion to win a free haptoglobin test, by filling out a survey form HERE.  Weird — the stuff we consider prizes as diabetics, ay?  ;)

Anyway, keep your eye on your heart health.  For my part, I'm feeling very O-L-D, as my endo started me on statins after my last checkup.  More about that here soon.

Disclaimer: Content created by the Diabetes Mine team. For more details click here.


This content is created for Diabetes Mine, a consumer health blog focused on the diabetes community. The content is not medically reviewed and doesn't adhere to Healthline's editorial guidelines. For more information about Healthline's partnership with Diabetes Mine, please click here.